WO2002012471A3 - Homologue de l'enzyme de conversion de l'angiotensine et utilisations - Google Patents

Homologue de l'enzyme de conversion de l'angiotensine et utilisations Download PDF

Info

Publication number
WO2002012471A3
WO2002012471A3 PCT/US2001/025059 US0125059W WO0212471A3 WO 2002012471 A3 WO2002012471 A3 WO 2002012471A3 US 0125059 W US0125059 W US 0125059W WO 0212471 A3 WO0212471 A3 WO 0212471A3
Authority
WO
WIPO (PCT)
Prior art keywords
converting enzyme
angiotensin converting
uses therefor
enzyme homolog
treating
Prior art date
Application number
PCT/US2001/025059
Other languages
English (en)
Other versions
WO2002012471A2 (fr
Inventor
Susan Acton
Keith E Robison
Frank Y Hsieh
Original Assignee
Millennium Pharm Inc
Susan Acton
Keith E Robison
Frank Y Hsieh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/635,501 external-priority patent/US6884771B1/en
Application filed by Millennium Pharm Inc, Susan Acton, Keith E Robison, Frank Y Hsieh filed Critical Millennium Pharm Inc
Priority to AU2001284794A priority Critical patent/AU2001284794A1/en
Publication of WO2002012471A2 publication Critical patent/WO2002012471A2/fr
Publication of WO2002012471A3 publication Critical patent/WO2002012471A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne la découverte de nouveaux gènes codant pour une enzyme de conversion de l'angiotensine, l'enzyme 2 de conversion de l'angiotensine (ACE-2). L'invention concerne également des méthodes thérapeutiques, de pronostic et de diagnostic permettant de traiter les troubles associés à la pression sanguine ainsi que divers types de conditions allergiques, entre autres. L'invention concerne en outre des analyses de criblage visant à identifier des composés permettant de traiter et de prévenir ces conditions.
PCT/US2001/025059 2000-08-09 2001-08-09 Homologue de l'enzyme de conversion de l'angiotensine et utilisations WO2002012471A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284794A AU2001284794A1 (en) 2000-08-09 2001-08-09 Angiotensin converting enzyme homolog and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/635,501 US6884771B1 (en) 1997-12-11 2000-08-09 Angiotensin converting enzyme homolog and uses therefor
US09/635,501 2000-08-09

Publications (2)

Publication Number Publication Date
WO2002012471A2 WO2002012471A2 (fr) 2002-02-14
WO2002012471A3 true WO2002012471A3 (fr) 2003-01-03

Family

ID=24548043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025059 WO2002012471A2 (fr) 2000-08-09 2001-08-09 Homologue de l'enzyme de conversion de l'angiotensine et utilisations

Country Status (2)

Country Link
AU (1) AU2001284794A1 (fr)
WO (1) WO2002012471A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098906A1 (fr) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Procedes et compositions permettant la modulation de l'activite de l'enzyme de conversion de l'angiotensine-2
US6900033B2 (en) 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
ES2424971T3 (es) 2002-06-19 2013-10-10 Apeiron Biologics Ag Activación de ECA2 para el tratamiento de enfermedades cardíacas, pulmonares y renales e hipertensión
EP1570854A4 (fr) * 2002-10-29 2008-07-30 Gen Kondoh Medicament contenant une angiotensine convertase
EP1723962A1 (fr) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
US20090186014A1 (en) * 2007-10-10 2009-07-23 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
EP2262491A1 (fr) * 2008-03-10 2010-12-22 Ore Pharmaceuticals Inc. Thérapie pour troubles du tube digestif proximal
EP2373806A1 (fr) * 2008-12-02 2011-10-12 F. Hoffmann-La Roche AG Dosages de criblage pour l'identification d'inhibiteurs bace2
EP3820498A1 (fr) * 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide pour le traitement de maladies
US20230174611A1 (en) * 2020-04-24 2023-06-08 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CA3179276A1 (fr) * 2020-05-20 2021-11-25 Charles C. Bailey Muteines ace2 et procedes d'utilisation de celles-ci
JP2024516605A (ja) * 2021-04-20 2024-04-16 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ コロナウイルス感染を処置するための新規組成物及び方法
EP4147702A1 (fr) 2021-09-13 2023-03-15 Medizinische Universität Graz Nouvelle combinaison d'héparine et de leurres ace2 pour le traitement de la covid-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974664A2 (fr) * 1998-05-13 2000-01-26 Smithkline Beecham Plc Polypeptides et polynucleotides humains ayant une homologie avec l'enzyme de conversion de l'angiotensine spécifique des testicules
EP0974644A1 (fr) * 1998-07-23 2000-01-26 Ajinomoto Co., Inc. Méthode pur la prodution de levure résistant à la congelation
WO2000018899A2 (fr) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Homologue d'enzyme de conversion d'angiotensine et son utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974664A2 (fr) * 1998-05-13 2000-01-26 Smithkline Beecham Plc Polypeptides et polynucleotides humains ayant une homologie avec l'enzyme de conversion de l'angiotensine spécifique des testicules
EP0974644A1 (fr) * 1998-07-23 2000-01-26 Ajinomoto Co., Inc. Méthode pur la prodution de levure résistant à la congelation
WO2000018899A2 (fr) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Homologue d'enzyme de conversion d'angiotensine et son utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN: "Two ACEs and a heart", NATURE, vol. 417, 20 June 2002 (2002-06-20), pages 799 - 802, XP002207554 *
DATABASE EMBL [online] 1 July 2000 (2000-07-01), "Homo sapiens angiotensin converting enzyme-like protein mRNA, complete cds", XP002207559, Database accession no. AF241254 *
DATABASE GENESEQ [online] 11 April 2000 (2000-04-11), "Human MPROT15 amino acid sequence #1", XP002207557, Database accession no. AAY67310 *
DATABASE GENESEQ [online] 11 April 2000 (2000-04-11), "Human MPROT15 coding sequence", XP002207558, Database accession no. AAZ59465 *
DATABASE GENESEQ [online] 25 July 2000 (2000-07-25), "A human angiotensin converting enzyme-2 (ACE-2) protein", XP002207555, Database accession no. AAY84562 *
DATABASE GENESEQ [online] 25 July 2000 (2000-07-25), "cDNA encoding a human angiotensin converting enzyme-2 (ACE-2)", XP002207556, Database accession no. AAA12764 *
DATABASE SWALL [online] 1 October 2000 (2000-10-01), "Angiotensin converting enzyme-like protein (ACE-related carboxypeptidase ACE2)", XP002207560, Database accession no. Q9NRA7 *
DONOGHUE MARY ET AL: "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.", CIRCULATION RESEARCH, vol. 87, no. 5, 1 September 2000 (2000-09-01), pages e1 - e9, XP002207553, ISSN: 0009-7330 *
TIPNIS ET AL.: "A human homolog of Angiotensin-converting enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33238 - 33243, XP002207551 *

Also Published As

Publication number Publication date
WO2002012471A2 (fr) 2002-02-14
AU2001284794A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2000018899A3 (fr) Homologue d'enzyme de conversion d'angiotensine et son utilisation
WO2002012471A3 (fr) Homologue de l'enzyme de conversion de l'angiotensine et utilisations
WO2002099589A3 (fr) Systeme et methode permettant de determiner la liquidite d'un credit
WO2002038107A3 (fr) Modulateurs de stat
WO2002072865A3 (fr) Procedes, kits et compositions se rapportant a des oligomeres de combinaison, et bibliotheques permettant leur preparation
WO2002031134A3 (fr) Nouveaux genes de serine protease apparentes a la dppiv
AU2003275613A1 (en) Novel fructosyl peptide oxidase and utilization thereof
WO2005123913A3 (fr) Compositions d'enzymes thermostables modifiees de façon reversible, et methodes de production et d'utilisation desdites compositions
HK1092841A1 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes
EP1163515A4 (fr) Outils diagnostiques et therapeutiques permettant de traiter les troubles de la tolerance glucidique
WO2002006534A3 (fr) Diagnostic de l'hypertension artérielle pulmonaire
WO2002062157A3 (fr) Traitement de melanges contenant des phosphatides
WO2005040107A3 (fr) Procedes pour fabriquer la simvastatine et leurs intermediaires
WO2003038444A3 (fr) Biomarqueurs de reponse hepatique
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
WO2002039122A3 (fr) Compositions et methodes permettant l'identification, l'evaluation, la prevention et la therapie des maladies cardio-vasculaires
WO2001062784A3 (fr) Proteines
WO2000014206A3 (fr) Cellulase mutante egiii, adn codant ces compositions d'egiii et leurs procedes de preparation
WO2003042357A3 (fr) Enzymes
WO2002072786A3 (fr) Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
WO2000050631A3 (fr) Compositions et methodes de controle de la modification de partenaires de liaison naturels
MXPA03007928A (es) Proceso mejorado para elaborar aderezos emulsificados para ensalada.
EP1019092A4 (fr) Outils therapeutiques et diagnostiques pour desordres lies a une mauvaise tolerance glucidique
WO2004009786A3 (fr) Modulateurs de l'activation des leucocytes, compositions bic et leurs procedes d'utilisation
WO2004003162A3 (fr) Enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP